WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 06-02-2024
AUM:
₹ 409.43 Cr
Expense Ratio
2.38%
Benchmark
BSE Healthcare TRI
ISIN
INF03VN01878
Minimum Investment
500.0
Minimum Topup
500.0
Minimum SIP Amount
100
Fund Manager
Ramesh Mantri
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth | 16.69 | - | - |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
14.082
Last change
-0.01 (-0.0568%)
Fund Size (AUM)
₹ 409.43 Cr
Performance
24.41% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
Fund Manager
Ramesh Mantri
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 7.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 6.64 |
| FORTIS HEALTHCARE LIMITED. EQ | 5.33 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.78 |
| JB Chemicals & Pharmaceuticals Limited | 4.59 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 4.44 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 4.24 |
| Krishna Institute Of Medical Sciences Limited | 3.88 |
| ANTHEM BIOSCIENCES PRIVATE LIMITED EQ NEW FV Rs. 2/- | 3.25 |
| Net Receivables / (Payables) | 2.93 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 88.95 |
| Chemicals | 1.58 |
| Capital Goods | 0.63 |
| Financial Services | 0.58 |